Progress in Cardiovascular Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: May 1, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(9), P. 7910 - 7910
Published: April 26, 2023
Recent advances have greatly improved our understanding of the molecular mechanisms behind atherosclerosis pathogenesis. However, there is still a need to systematize this data from general pathology perspective, particularly with regard atherogenesis patterns in context both canonical and non-classical inflammation types. In review, we analyze various typical phenomena outcomes cellular pro-inflammatory stress atherosclerosis, as well role endothelial dysfunction local systemic manifestations low-grade inflammation. We also present features immune development productive stable unstable plaques, along their similarities differences compared There are numerous factors that act inducers inflammatory process including vascular endothelium aging, metabolic dysfunctions, autoimmune, some cases, infectious damage factors. Life-critical complications such cardiogenic shock severe strokes, associated acute hyperinflammation. Additionally, critical atherosclerotic ischemia lower extremities induces paracoagulation chronic Conversely, sepsis, other conditions, diseases contribute atherogenesis. summary, can be characterized an independent form inflammation, sharing but having fundamental variants (classic vasculitis).
Language: Английский
Citations
126
Journal of the American College of Cardiology, Journal Year: 2022, Volume and Issue: 79(8), P. 757 - 768
Published: Feb. 21, 2022
Language: Английский
Citations
101
Atherosclerosis, Journal Year: 2022, Volume and Issue: 349, P. 42 - 52
Published: May 1, 2022
Language: Английский
Citations
71
Chemical Reviews, Journal Year: 2024, Volume and Issue: 124(3), P. 929 - 1033
Published: Jan. 29, 2024
RNA-based therapies have catalyzed a revolutionary transformation in the biomedical landscape, offering unprecedented potential disease prevention and treatment. However, despite their remarkable achievements, these encounter substantial challenges including low stability, susceptibility to degradation by nucleases, prominent negative charge, thereby hindering further development. Chemically modified platforms emerged as strategic innovation, focusing on precise alterations either RNA moieties or associated delivery vectors. This comprehensive review delves into platforms, underscoring significance augmenting performance translational prospects of therapeutics. It encompasses an in-depth analysis various chemically that been instrumental propelling therapeutics toward clinical utility. Moreover, scrutinizes rationale behind diverse chemical modification techniques aiming at optimizing therapeutic efficacy molecules, facilitating robust management. Recent empirical studies corroborating enhancement through modifications are highlighted. Conclusively, we offer profound insights transformative impact drugs delineates prospective trajectories for future development integration.
Language: Английский
Citations
52
Cell, Journal Year: 2024, Volume and Issue: 187(7), P. 1685 - 1700.e18
Published: March 1, 2024
Language: Английский
Citations
33
Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)
Published: March 15, 2025
Extracellular proteins play pivotal roles in both intracellular signaling and intercellular communications health disease. While recent advancements proximity labeling (PL) methods, such as peroxidase- photocatalyst-based approaches, have facilitated the resolution of extracellular proteomes, their vivo compatibility remains limited. Here, we report TyroID, an vivo-compatible PL method for unbiased mapping with high spatiotemporal resolution. TyroID employs plant- bacteria-derived tyrosinases to produce reactive o-quinone intermediates, enabling multiple residues on endogenous bioorthogonal handles, thereby allowing identification via chemical proteomics. We validate TyroID's specificity by proteomes HER2-neighboring using affibody-directed recombinant tyrosinases. Demonstrating its superiority over other enables including HER2-proximal tumor xenografts, quantifying turnover plasma hippocampal-specific live mouse brains. emerges a potent tool investigating protein localization molecular interactions within living organisms. is that maps through efficiently labels study interactions.
Language: Английский
Citations
2
Frontiers in Physiology, Journal Year: 2022, Volume and Issue: 13
Published: Aug. 30, 2022
Among the diseases causing human death, cardiovascular disease (CVD) remains number one according to World Health Organization report in 2021. It is known that atherosclerosis pathological basis of CVD. Low-density lipoprotein (LDL) plays a pivotal role initiation and progression atherosclerotic CVD (ASCVD). LDL cholesterol (LDL-C) traditional biological marker LDL. However, large numbers patients who have achieved recommended LDL-C goals still ASCVD risk. In multiple prospective studies, particle (LDL-P) reported be more accurate predicting risk than LDL-C. LDL-Ps differ size, density chemical composition. Numerous clinical studies proved atherogenic mechanisms are determined not only by size but also modifications. Of note, small dense (sdLDL) particles possess stronger ability compared with intermediate subfractions. Besides, oxidized (ox-LDL) another factor atherosclerosis. lipid-lowering drugs, statins induce dramatic reductions LDL-P lesser extend. Recently, proprotein convertase subtilsin/kexin type 9 inhibitors (PCSK9i) been demonstrated effective lowering levels LDL-C, LDL-P, as well events. this article, we will make short review metabolism, discuss discordance between outline action focusing on sdLDL ox-LDL, summarize methods used for measurement subclasses, conclude advances LDL-lowering therapies using PCSK9i.
Language: Английский
Citations
70
American Journal of Preventive Cardiology, Journal Year: 2022, Volume and Issue: 12, P. 100371 - 100371
Published: Aug. 6, 2022
Atherosclerotic cardiovascular disease (ASCVD) is epidemic throughout the world and etiologic for such acute events as myocardial infarction, ischemic stroke, unstable angina, death. ASCVD also impacts risk dementia, chronic kidney peripheral arterial mobility, impaired sexual response, a host of other visceral impairments that adversely impact quality rate progression aging. The relationship between low-density lipoprotein cholesterol (LDL-C) one most highly established investigated issues in entirety modern medicine. Elevated LDL-C necessary condition atherogenesis induction. Basic scientific investigation, prospective longitudinal cohorts, randomized clinical trials have all validated this association. Yet despite enormous number which support need reducing burden atherogenic blood, percentage high very high-risk patients who achieve stratified target reductions low has remained last thirty years. Atherosclerosis preventable disease. As clinicians, time come us to take primordial primary prevention more serously. Despite plethora therapeutic approaches, large majority at are poorly or inadequately treated, leaving them vulnerable progression, events, poor aging due loss function multiple organs. Herein we discuss greatly intensify efforts reduce risk, decrease burden, provide comprehensive earlier assessment optimally prevent its complications. Evidence presented treatment should aim far lower goals management, into account many factors than commonly employed today begin significantly life.
Language: Английский
Citations
62
Cardiovascular Diabetology, Journal Year: 2022, Volume and Issue: 21(1)
Published: Dec. 5, 2022
Abstract Apolipoprotein C1 (apoC1) is a small size apolipoprotein whose exact role not totally clarified but which seems to modulate significantly the metabolism of lipoproteins. ApoC1 involved in triglyceride-rich lipoproteins by inhibiting binding very low density (VLDL) VLDL-receptor (VLDL-R), lipoprotein receptor (LDL-R) and LDL related protein (LRP), reducing activity lipase (LPL) stimulating VLDL production, all these effects leading increase plasma triglycerides. takes also part high (HDL) Cholesterol Ester Transfer Protein (CETP). The functionality apoC1 on CETP impaired diabetes that might account, at least part, for increased observed patients with diabetes. Its different possible modulation inflammation makes net impact cardiometabolic risk difficult figure out be considered as pro-atherogenic or anti-atherogenic depending overall metabolic context. Making link between total levels cardio-metabolic diseases due exchangeability this biological depend essentially its association HDL. humans entirely elucidated further studies are needed determine precise lipid pleiotropic vascular wall biology. In review, we will present data structure distribution among lipoproteins, HDL discuss links apoC1, atherosclerosis
Language: Английский
Citations
53
Diabetes & Metabolism Journal, Journal Year: 2022, Volume and Issue: 46(4), P. 517 - 532
Published: July 28, 2022
Statins are the cornerstone of prevention and treatment atherosclerotic cardiovascular disease (ASCVD). However, even under optimal statin therapy, a significant residual ASCVD risk remains. Therefore, there has been an unmet clinical need for novel lipid-lowering agents that can target low-density lipoprotein cholesterol (LDL-C) other atherogenic particles. During past decade, several drugs have developed dyslipidemia. Inclisiran, small interfering RNA targets proprotein convertase subtilisin/kexin type 9 (PCSK9), shows comparable effects to PCSK9 monoclonal antibodies. Bempedoic acid, ATP citrate lyase inhibitor, is valuable option patients with intolerance. Pemafibrate, first selective peroxisome proliferator-activated receptor alpha modulator, showed favorable benefit-risk balance in phase 2 trial, but large 3 trial (PROMINENT) was recently stopped futility based on late interim analysis. High dose icosapent ethyl, modified eicosapentaenoic acid preparation, benefits. Evinacumab, angiopoietin-like (ANGPTL3) antibody, reduces plasma LDL-C levels refractory hypercholesterolemia. Novel antisense oligonucleotides targeting apolipoprotein C3 (apoC3), ANGPTL3, lipoprotein(a) significantly attenuated their molecules beneficial associated dyslipidemias. Apolipoprotein A1 (apoA1) considered as potential exploit athero-protective high-density (HDL-C), solid evidence necessary. In this review, we discuss mode action outcomes these beyond statins.
Language: Английский
Citations
48